Alpha Teknova, Inc. (TKNO)
| Market Cap | 382.26M +60.5% |
| Revenue (ttm) | 43.70M +12.3% |
| Net Income | -16.77M |
| EPS | -0.31 |
| Shares Out | 53.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,561 |
| Open | 7.30 |
| Previous Close | 7.31 |
| Day's Range | 7.01 - 7.35 |
| 52-Week Range | 1.91 - 7.84 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 8.60 (+20.79%) |
| Earnings Date | Aug 5, 2026 |
About TKNO
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and dr... [Read more]
Financial Performance
In 2025, Alpha Teknova's revenue was $40.52 million, an increase of 7.35% compared to the previous year's $37.75 million. Losses were -$17.26 million, -35.47% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for TKNO stock is "Strong Buy." The 12-month stock price target is $8.6, which is an increase of 20.79% from the latest price.
News
Alpha Teknova Transcript: Micro-Cap Virtual Conference
The company highlighted record revenue growth, improved profitability metrics, and raised guidance, driven by strong demand in biopharma and diagnostics. Strategic investments in AI, commercial capabilities, and potential acquisitions position it for continued expansion, with EBITDA and cash flow positivity targeted by 2027.
BTIG upgrades Alpha Teknova to Buy on improving fundamentals
BTIG upgraded Alpha Teknova (TKNO) to Buy from Neutral with an $8 price target The company reported a “beat and raise” Q2 on improving fundamentals amid a better funding environment…
Alpha Teknova upgraded to Buy from Neutral at BTIG
BTIG upgraded Alpha Teknova (TKNO) to Buy from Neutral with an $8 price target
Alpha Teknova price target raised to $8 from $7 at Roth Capital
Roth Capital analyst Max Masucci raised the firm’s price target on Alpha Teknova (TKNO) to $8 from $7 and keeps a Buy rating on the shares. Alpha Teknova’s recovery continued…
Alpha Teknova Earnings Call Transcript: Q2 2026
Record Q2 2026 revenue grew 18% year-over-year, driven by broad-based demand except for cell and gene therapy. Raised 2026 revenue guidance to $45–$47M, launched Build-Tek AI configurator, and expect commercial investments to drive further growth in 2027.
Alpha Teknova Earnings release: Q2 2026
Alpha Teknova released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Alpha Teknova Slides: Q2 2026
Alpha Teknova has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Alpha Teknova Quarterly report: Q2 2026
Alpha Teknova has published its Q2 2026 quarterly earnings report on August 5, 2026.
Teknova Reports Second Quarter 2026 Financial Results
Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year Company raises 2026 revenue guidance to $45-47 million Launched proprietary AI-powered Build-Tek™ custom o...
Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes
HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Alpha Teknova (TKNO) with a Buy rating and $7 price target The company provides diversified exposure to several “key growth offshoots” within life sciences markets…
Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026
HOLLISTER, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova reports Q1 EPS (8c) vs. (9c) last year
Reports Q1 revenue $11.08M, consensus $10.22M. “We had a great start to 2026,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “The substantial investments we’ve made since 2...
Alpha Teknova backs FY26 revenue view $42M-$44M, consensus $43.01M
Matt Lowell, Teknova’s Chief Financial Officer, added, “We delivered strong financial results in the first quarter 2026 compared to 2025, including 13% revenue growth and significant improvements in A...
Alpha Teknova Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% revenue growth, led by an 85% surge in Clinical Solutions and improved gross margin. Investments in commercial capabilities and automation are expected to drive double-digit growth in 2027, with positive adjusted EBITDA targeted by year-end 2027.
Alpha Teknova Slides: Q1 2026
Alpha Teknova has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Alpha Teknova Earnings release: Q1 2026
Alpha Teknova released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Alpha Teknova Quarterly report: Q1 2026
Alpha Teknova has published its Q1 2026 quarterly earnings report on May 6, 2026.
Teknova Reports First Quarter 2026 Financial Results
First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year Company reaffirms 2026 revenue guidance of $42-44 million
Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of n...
Alpha Teknova Proxy statement: Proxy filing
Alpha Teknova filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Alpha Teknova Proxy statement: Proxy filing
Alpha Teknova filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Alpha Teknova Transcript: Sidoti March Small-Cap Virtual Conference
Revenue reached $40.5 million in 2025 with strong growth in both catalog and custom GMP products. Investments in sales, marketing, and technology, along with a new GMP facility, position the business for profitability by 2027. Clinical Solutions and Lab Essentials segments drive future upside as therapies advance through clinical stages.
Alpha Teknova Earnings Call Transcript: Q4 2025
Revenue grew 7% in 2025 with improved gross margins and reduced losses. Investments in commercial capabilities and a recovering biotech market are expected to drive future growth, with positive adjusted EBITDA targeted by end of 2027.
Alpha Teknova Annual report: Q4 2025
Alpha Teknova has published its Q4 2025 annual report on February 26, 2026.